INTRODUCTION 1
The formation of functional blood and lymphatic vessels is a keystone during embryo 2 development and is essential for supplying all organs with oxygen and nutrients and 3 for disposal of catabolites. Vascular Endothelial Growth Factors (VEGFs) are the main 4 drivers of vasculogenesis, the de novo formation of vessels, and angiogenesis, the 5 formation of new vessels from preexisting vasculature (reviewed in (Smith et al., 2015; 6 Shibuya, 2014; Moens et al., 2014) . VEGFs activate three VEGF receptors (VEGFR-7 1, -2 and -3), representing the type V subfamily of receptor tyrosine kinases (RTKs) in 8 the human kinome and are indispensable for vessel development. The molecular 9 details of the regulatory processes specific for this RTK subfamily are therefore of high 10 medical relevance. 11
Mutation or ablation of a specific VEGFR gave rise to distinct disease profiles 12 (Shibuya, 2014) documenting signal diversity among these three receptors. Both 13 ablation of VEGFR-1 and -2 were embryonic lethal; the former due to complete 14 disorganization of blood vessels (Fong et al., 1995) , the latter because of the complete 15 absence of endothelial cells (Shalaby et al., 1995) . Interestingly, expression of a kinase 16 deficient VEGFR-1 variant did not lead to embryonic lethality and mice expressing this 17 receptor variant had only minor defects (Hiratsuka et al., 1998; Hiratsuka et al., 2001) . 18
Deregulated expression of a soluble splice variant of VEGFR-1, encompassing only 19 the extracellular domain (ECD) and acting as a ligand trap (Kendall and Thomas, 1993) , 20 is associated with vascular defects such as the placental deficiency preeclampsia 21 (Luttun and Carmeliet, 2003; Maynard et al., 2003) , or corneal and retinal avascularity 22 (Luo et al., 2013; Ambati et al., 2006) . This variant is thus a potentially interesting target 23 for drug development. 24 RTK activation requires ligand-mediated dimer or multimer formation, which 25 instigates transmembrane signaling resulting in activation of the intracellular kinase 26 RESULTS 1
Structure determination of the VEGFR-1 extracellular domain/VEGF-A complex 2
To obtain detailed structural information for future drug design we determined the 3 organization of the full-length ECD of VEGFR-1 in complex with VEGF-A using X-ray 4 crystallography. Human VEGFR-1 baculovirus constructs encompassing Ig-domains 5 D1-7, D1-6, and D2-7 ( Figure 1A) were expressed in insect cells, purified, and 6 crystallized in complex with VEGF-A. Complex formation between ligand and receptor 7 ECD proteins and monodispersity of the complexes was determined by size exclusion 8 chromatography coupled to multi-angle light scattering (SEC-MALS) and small angle 9 X-ray scattering (SAXS) (Supplemental Methods). Complex formation was already 10 observed during protein purification as VEGF-A co-eluted from a SEC column together 11 with the VEGFR-1 ECD ( Figure S1A ) and molecular weight determination by SEC-12 MALS clearly indicated 1:1 dimer formation of the full-length VEGFR-1 ECD with 13 VEGF-A ( Figure S1B ). In addition, small angle X-ray scattering analysis in solution 14 (SAXS) showed an increase in the radius of gyration (Rg) and of the maximal length 15 of the complex (Dmax) in the presence of ligand as observed in the distance distribution 16 function, confirming the presence of a stable ligand/receptor complex ( Figure S1C ). 17
After various optimization rounds we obtained crystals of the D1-6 complex 18 diffracting to 4 Å, which we found suitable for structure determination (Table 1) . 19
Crystals belonged to space group C2 with one complex per asymmetric unit and a 20 solvent content of 70%. Enabled by a novel data collection strategy (Weinert et al., 21 2015) , the structure of the VEGFR-1 D1-6/VEGF-A complex was solved by a 22 combination of molecular replacement and single wavelength anomalous dispersion 23 (MR-SAD) using iodide-soaked crystals ( Figure 1B) . The resulting electron density 24 map revealed the D2 region and the ligand, positioned by molecular replacement, and 25 contained continuous electron density for the missing Ig-domains ( Figure S2 ). D3, D4, 26 6 and D5 were placed by additional rounds of phased molecular replacement, and proper 1 sequence assignment was performed by replacing the molecular replacement search 2 models with the corresponding homology models generated by the SWISS-MODEL 3 homology modeling server. D1 and D6, because of their less well-defined electron 4 density and the lack of good homology modeling templates, were modeled using the 5 Foldit structure prediction game (Cooper et al., 2010) . The best D1 and D6 models 6 were selected for further manual refinement based on their performance as search 7 models in molecular replacement ( Figure S3 ). 8
Anomalous scattering of Selenium-Methionine (Se-Met) is a powerful structure 9 and sequence validation tool. In the absence of diffracting Se-Met derivative crystals 10 we turned to sulfur-SAD to validate our final model of the VEGFR-1 D1-6/VEGF-A 11 complex ( Figure 2 ). With weakly diffracting crystals, careful data collection was crucial 12 to obtain the accuracy necessary for resolution of the small anomalous signals. Despite 13 the crystals diffracting only to 4 Å resolution, more than half of all anomalous scatterers, 14
including every disulfide bridge in the Ig-domains and the VEGF-A ligand, as well as 15 several methionines were assigned in the anomalous difference Fourier maps, 16 verifying subunit placement as well as sequence assignment ( Figure 2B ). In addition, 17 positive electron density present in the Fo-Fc maps for N-linked glycans around the 18 asparagine residues predicted to be glycosylated further aided in exact sequence 19 assignment. 20
To complete the molecular structure of the VEGFR-1 ECD, we also used 21 crystals of the VEGFR-1 D2-7/VEGF-A complex diffracting to 4.8 Å. The D1-6 complex 22 structure was used as a search model for molecular replacement of the D2-7/VEGF-A 23 complex ( Figure 1C ). To create a composite model of the D1-7/VEGF-A complex we 24 superimposed the two structures, D1-6/VEGF-A and D2-7/VEGF-A (RMSD of 1.76 Å 25 for 1128 residues of the D2-6 region) and connected the D7 portion of the D2-7/VEGF-26 7 A model with the D1-6/VEGF-A based model ( Figure 1D ). 1 2
Overall architecture of the VEGFR-1 ECD/VEGF-A complex 3
The structures of the D1-6 and the D2-7 VEGF-A complexes both show 2:2 4 stoichiometry and contain two sets of 1:1 complexes in the asymmetric unit related by 5 2-fold non-crystallographic symmetry. In the composite model of the VEGFR-1 6 ECD/VEGF-A complex ( Figure 1D ), two receptor chains are bridged with the dimeric 7 VEGF-A ligand in the D2-3 region and related by two-fold symmetry throughout the 8 long axis of the complex. The complex has overall dimensions of ~160 Å × ~230 Å × 9 ~80 Å and is characterized by the existence of three cavities: the upper one formed 10 between the VEGF-A dimer, D3 and D4 domains of two receptor chains (dimensions 11 ~65 Å × ~50 Å); the middle one between the D4 and D5 domains (~30 Å × ~15 Å); and 12 the lower one between the D5, D6 and D7 domains (~55 Å × ~50 Å). VEGF-A binding 13 to D2 and D3 induces a twisted arrangement between these two domains, with a 14 bending angle of ~135°. This is followed by intertwining of receptor chains in D4-5 15 bringing two protomers in close proximity to each other. The twist angle between D4 16 and D5 within the same chain is 60°. Additional homotypic contacts are observed 17 between D7 domains. In our model the D7 dimer deviates from the D1-6/VEGF-A 2-18 fold axis, which is a consequence of crystal packing of the D2-7/VEGF-A complex. This 19 finding suggests flexibility in the D6-7 region due to a longer linker between these two 20
domains. 21
To confirm the overall structure of the VEGFR-1 ECD/VEGF-A complex we 22 additionally visualized the complex by negative stain electron microscopy ( Figure 3A ). 23
The calculated class averages showed excellent agreement with projections of the 24 crystal structure ( Figure 3B ). All class averages show dimeric VEGFR-1 ECD chains 25 bridged by VEGF-A. Interestingly, a slight bend is observed in the membrane-proximal 26 8 region confirming the kinked D6-D7 region seen in the D2-7/VEGF-A crystal structure. 1
As there is a clear preference for the complex to adsorb to the grid showing the front 2 view, only one class was generated of the side view. 3 4 Individual Ig-domains are all glycosylated and apart from D6 belong to the I-set 5 of the Ig-domain superfamily 6 This is the largest structure determined so far in the VEGF receptor family and allows 7 us to describe the structure and arrangement of the individual Ig-domains of VEGFR-8 1. With the exception of D6, all Ig-domains of VEGFR-1 belong to the I-set of the Ig-9 domain superfamily. D1 (residues 32-130) was modeled by Foldit players and 10 subsequently rebuilt during refinement. Although the experimental electron density 11 map suggested large disordered regions, the 2Fo-Fc maps allowed us to build all 12 residues except the D-E loop (78-84), which was disordered. Additional electron 13 density around N100 confirmed the presence of an N-linked glycan, and the position 14 of a disulfide bridge between C53 and C107 was validated by sulfur-SAD experiments. 15
The structure of D2 (residues 132-225) was solved before (Wiesmann et al., 1997) and 16 our structure additionally shows N-glycosylation of N164 and N196. D1 is bent away 17 by ~ 80° from D2 and has no contact with the ligand. The bent conformations of the 18 D1-2 modules of VEGFR-1 and VEGFR-3 are very similar and 19 can be aligned with an RMSD of 1.66 Å for 161 residues ( Figure S4 ). D3 (residues 20 226-330) is an elongated Ig-domain with N-glycosylation of N251 and N323. D4 21 (residues 333-426) is a smaller Ig-domain not disulfide bridged between the β-sheets 22 and lacking β-strand 4. D4 is glycosylated at N402 and N417. D5 (residues 428-554) 23
is the largest Ig-domain in VEGF receptors due to a long C-D loop that connects two 24 β-sheets. Residues 472-486 within this region were disordered and therefore omitted 25 from the final model. In D5 we observed N-glycosylation of N547 and verified the 26 positions of the disulfide bridge between C454 and C535 and of all methionines by S-1 SAD ( Figure 2 ). With our structure we obtained, for the first time, structural information 2 on D6 of VEGF receptors, which belongs to the C2-set of Ig-domains. D6 contains 3 strands of intermediate length in both β-sheets, a disulfide bridge between C577 and 4 C636, and an N-linked glycan at N625. D7 (residues 661-750) was modeled using D7 5 of VEGFR-2 (PDB ID: 3KVQ) as a template and, due to the low resolution of the 6 VEGFR-1 D2-7 complex data, we do not further discuss its structural details. However, 7 D7 of the two protomers form a dimeric arrangement as described in the crystal 8 structure of isolated VEGFR-2 D7 (Yang et al., 2010) . 9
10

VEGFR-1 D3 contributes to ligand binding and determines ligand specificity 11
Ligand binding to VEGFR-1 takes place in Ig-domains 2 and 3. With our structure we 12 can now describe the complete ligand binding site of VEGFR-1, while earlier published 13 complex structures contained only D2 (Christinger et al., 2004; Iyer et al., 2010; 14 Wiesmann et al., 1997) . Each receptor chain interacts with both VEGF-A protomers 15 ( Figure 4A ). The surface buried on one receptor chain by the bound VEGF-A dimer is 16 ~1500 Å 2 , with D2 and D3 contributing similar interface areas (~800 Å 2 for D2 versus 17 ~700 Å 2 for D3). VEGF-A residues interacting with D2 are part of the N-terminal helix 18 α1 of the ligand protomer A (M17, F18, Y21, Q22 and Y25); and of the strands β2 (I46, 19 K48), β4 (Q79, M81, I83) and β5 (Q89, I91) of the protomer B ( Figure 4B ). While the 20 interface between ligand and D2 is largely hydrophobic, the contacts with D3 are 21 hydrophilic comprising a number of ionic interactions. There is an overall positive 22 charge of the D3 region that comes in contact with the ligand. Several charged residues 23 from all three loops (L1, L2 and L3) of VEGF-A interact with D3. The most prominent 24 conserved residue is E64 in L2 that engages 5 charged residues located in D3 of the 25 receptor (N259, R261, R280, Q284 and N290) in hydrogen bond and salt bridge type 26 interactions. Another residue from L2, D63, forms salt bridges with R224 located in the 1 D2-3 linker ( Figure 4C ). In addition, E44 in L1 and K84 in L3 form hydrogen bonds with 2 Q263 of D3. Loops 1 and 3 also carry hydrophobic residues such as P40, I43 and P85 3 that form complementary surface with D3 of VEGFR-1. I43 protrudes into the 4 hydrophobic pocket on the D3 surface formed by V262, M264, V278 and F292. 5 Structural comparison of receptor binding epitopes for the VEGFR-1 ligands 6 VEGF-A, PlGF and VEGF-B shows that all three ligands interact similarly with D2 of 7 VEGFR-1 ( Figure S5 ). The interaction between the loop L2 of the three ligands with 8 D3 is also very similar, since D63 of VEGF-A is strictly conserved and E64 is conserved 9 in PlGF and substituted by aspartate in VEGF-B. Differences are observed in the way 10 how the three ligands interact through the loops L1 and L3 with D3 of VEGFR-1. While 11 the sequence and structure conservation in these regions is high between VEGF-A 12 and PlGF, this is not the case for VEGF-B. Superposition of the VEGFR-1 D2/VEGF-13 B complex onto our structure enables visualization of the possible structural 14 arrangement of the VEGF-B loops L1 and L3 in respect to receptor domain D3. It 15 appears that these loops are moved away from D3 and not involved in any interactions. 16
These findings agree with a recent study that showed that 17 VEGF-B does not require D3 interactions for high-affinity binding and does not promote 18 signaling downstream of VEGFR-1. PlGF and VEGF-A, on the other hand, are 19 angiogenic ligands and the L1 interaction with D3 is important for receptor activation. 20
21
VEGFR-1 D4-5 form homotypic interactions in the presence of ligand 22
The structure of the VEGFR-1 D1-6/VEGF-A complex reveals homotypic interactions 23 in D4 and D5, covering altogether a solvent-accessible area of ~1000 Å 2 per chain 24 ( Figure 5A and B). The interface between the Ig-domains 4 is small (~165 Å 2 per chain) 25 and includes R351 located in the A-B loop of one D4 that shares a hydrogen bond with 26 S380 located in the C-E loop of the other D4 ( Figure 5C ). The interactions between the 1 residues in the E-F loop proposed earlier based on a KIT structure (Yuzawa et al., 2 2007) are not present in our structure. 3
The homotypic contacts in D5 are, like in VEGFR-3, centered on the fully 4 conserved residues T455 ( -strand B) and K517 ( -strand E) that form hydrogen bonds 5 with the backbone atoms of S436 and A434 of the other chain ( Figure 5C ). 6
Furthermore, a glutamate residue in the D-E loop (E513) conserved in all VEGFRs 7 interacts via hydrogen bond with Q429 and via salt bridge with K433 of the other chain 8 ( Figure 5E ). While the fully conserved residues are part of the rigid β-sheet, their 9 interacting partners are not conserved and belong to the flexible strands A and A' and 10 the helical protrusion between them. 11 12
Homotypic interactions contribute to ligand affinity and full receptor activity 13
The purified receptor ECD was monomeric indicating that the homotypic interactions 14 in D4-7 are weak and apparently depend on ligand-mediated receptor dimerization 15 ( Figure S1 ). We used isothermal titration calorimetry (ITC) to assess the contribution 16 of the membrane-proximal Ig-domains 4-7 to the binding affinity of the full-length ECD 17 of VEGFR-1 for VEGF-A. Similar to VEGFR-3 , D1-7 of 18 VEGFR-1 had significantly higher affinity for the ligand than D1-3 ( Figure 6A ). The 19 binding affinity of VEGFR-1 D1-7 for VEGF-A was in the low nanomolar range (~ 2 20 nM), while the affinity of VEGF-A for VEGFR-1 D1-3 was 20 times lower i.e. ~ 50 nM. 21
Binding of VEGF-A to D1-3 was entropically favored, whilst binding to D1-7 was 22 enthalpically driven ( Figure 6B ). The presence of Ig-domains 4-7 thus increased 23 binding affinity for VEGF-A, presumably due to stabilization through homotypic 24 receptor-receptor contacts in D4-7. 25 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Based on the structural data described here and in our earlier work (Leppänen 1 et al., 2013; Brozzo et al., 2012; Leppänen et al., 2010; Ruch et al., 2007; Kisko et al., 2 2011) we predicted that the contacts in D5 are essential for receptor function. We 3 therefore mutated the residues involved in the D5 interaction and determined receptor 4 activity in transfected NIH 3T3 cells. The activity of VEGFR-1 was too low to obtain 5 high quality functional data and we therefore mutated the corresponding residues in 6 D5 of VEGFR-2 based on a homology model of this domain (for details of the mutants 7 used see Figure 5E ). In the mutant T446E/K512A residue T446 was replaced by E and 8 K512 by A, thus preventing hydrogen bond and salt bridge formation in the dimeric 9 receptor complex. This mutant showed a decrease in ligand-induced VEGFR-2 10 phosphorylation by 60% reflecting impaired receptor activation ( Figure 5D left panel). 11
To determine the functionality of the VEGFR-1 D5 interface we also created a chimeric 12 VEGFR (VEGFR-1/2) consisting of the VEGFR-1 ECD and the intracellular domain of 13 VEGFR-2. Mutant E513K/K517A showed a reduction in receptor kinase activity by 14 50% ( Figure 5D right panel). Taken together, these data show that the contacts in D5 15 revealed by our VEGFR-1 ECD/VEGF-A structure are essential for receptor activation. 16
17
DISCUSSION 18
We present here the first full-length VEGF receptor ECD structure in complex with one 19 of its ligands revealing all structural details of VEGF-A binding to VEGFR-1. Most 20 importantly, our structure shows the structural details of the homotypic contacts in D4-21 7 in the context of the full-length receptor ECD. Our functional analysis of these 22 interactions proves their relevance for receptor activation. We propose that exact 23 positioning of ligand-bound receptor protomers in active dimers, which is essential for 24 kinase activation, is mediated by the concerted interplay of ligand-receptor interactions 25 in D2-3 and receptor-receptor interactions in D4, D5 and D7. 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1
Specificity of ligand binding to VEGFRs 2
Although earlier studies did not report increased affinity towards VEGF-A when 3
including Ig-domain 3 in VEGFR-1 constructs (Wiesmann et al., 1997) , our structure 4 shows significant D3 interactions with all three connecting loops of VEGF-A. We 5 propose that the role of D3/VEGF interactions is to trigger receptor ECD intertwining 6 and to induce homotypic interactions in D4-5 and D7. In addition, we identify D3/VEGF 7 interaction as a determinant for ligand specificity and as a sensor for modification of 8 homotypic interactions in D4-7 depending on the strength of the induced twist between 9 D2-3. This might ultimately lead to a different functional output induced by distinct 10 VEGF ligands. With the structure of the VEGFR-1 ECD/VEGF-A complex and the 11 comparison of receptor binding epitopes in VEGF-A, PlGF and VEGF-B we provide a 12 structural basis for understanding the different signaling outputs generated by these 13 three VEGFR-1 ligands. Our data thus provide structural evidence for the role of the 14 VEGFR-1 D3/ligand interface in receptor signaling ( Figure S5) . 15
The next question that arises is why do VEGF-C, -D and -E not bind to VEGFR-16 1? Sequence conservation between different VEGF family members varies in the three 17 binding loops. While the residues in the loop L2 are highly conserved within the VEGF 18 family, there are significant sequence and structural differences in the N-terminal helix 19 α1 and in the loops L1 and L3, which presumably define receptor specificity of the 20 ligands. The interaction between residues E44 in L1 and K84 in L3 of VEGF-A with D3 21 of VEGFR-1 are not conserved in VEGF-C, D, and E ( Figure S6 ), and may thus 22 determine receptor specificity. 23
Structural comparison of VEGF-A binding to VEGFR-1, as described here, with 24 binding to VEGFR-2 (PDB ID: 3V2A) shows similar type of interactions. The ligands in 25 the two structures have very similar structures and can be aligned with an RMSD of 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 0.86 Å for 190 aligned residues. The difference exists in the orientation of D3 towards 1 D2 where VEGF-A binding to VEGFR-1 induces a stronger twist by 11° between D2 2 and D3 ( Figure S4 ). With the exception of E64 in VEGFR-1, which engages more 3 residues in salt bridge and hydrogen-bond type interactions, loop L2 interacts similarly 4 with D3 of VEGFR-1 or VEGFR-2. 5
To fully understand the differences in the signaling output by VEGFRs upon 6 binding to a particular VEGF ligand, one needs to consider also the role of co-7 receptors. Distinct ligands promote ternary complex formation, which has an impact on 8 receptor trafficking and signaling . 9
Role of homotypic receptor contacts in VEGFR activation 11
Our structural analysis describes for the first time the details of homotypic contacts in 12 the membrane proximal domain of type V RTKs in the context of a full-length ligand-13 bound receptor ECD. In addition, we show that mutation of the interacting interface 14 attenuates receptor activation. This is in agreement with earlier findings showing that 15 homotypic contacts in D4-7 are functionally relevant for VEGFR-3 (Leppänen et al., 16 2013) and VEGFR-2 (Yang et al., 2010) and documents the strong similarity with type 17 III RTKs such as PDGFR (Yang et al., 2008) and Kit (Yuzawa et al., 2007; Reshetnyak 18 et al., 2015; Yang et al., 2010) . The described ectodomain contacts in the membrane 19 proximal domain are apparently essential for the tight control of type III and V 20 receptors. Mutation of the interface involved in these homotypic contacts renders e.g. 21 KIT oncogenic (Reshetnyak et al., 2015) and promotes ligand-independent kinase 22 activation. We also showed earlier that antibody like molecules such as DARPins 23 (Stumpp et al., 2008; Binz et al., 2004) binding D4 or D7 of VEGFR-2, block receptor 24 signaling (Hyde et al., 2012) . 25
Receptor-receptor interactions in D4 revealed in this work are in agreement with 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 earlier studies on VEGFR-1 (Barleon et al., 1997) and VEGFR-2 (Shinkai et al., 1998) 1 that pointed at the importance of this domain in ligand-induced receptor dimerization. 2 Similar interactions were, on the other hand, not observed in the VEGFR-3 D4-5 3 structure . Since the D4 interactions in VEGFR-1 occur through 4 the C-E loop, which is longer in this receptor compared to the other homologs, they 5 might be relevant for VEGFR-1 functionality. Interestingly, in our structure we did not 6 observe the previously proposed D4 interactions between residues in the E-F loop 7 (Yuzawa et al., 2007) . However, careful analysis of the D4 residues facing each other 8 reveals that R382 in the C-E loop and D394 in the E-F loop could, by simple 9 modification of their chi angles, form a salt bridge. This putative D4 interface would be 10 very similar to the interactions in D4 of KIT (Yuzawa et al., 2007) and D7 of VEGFR-2 11 (Yang et al., 2010) . In the current structure R382 forms an internal salt bridge with 12 D399. Whether the side chains of R382 and D394 may adopt multiple conformations 13 cannot be determined at the resolution of our structure ( Figure S7 ). 14 Homotypic interactions in D5 have interesting structural characteristics with one 15 interacting side composed of a rigid β-sheet (β-strands B, D and E) and the other side 16 being more flexible (strands A and A') ( Figure 5C ). Curiously, the flexible strands A 17 and A' are directly linked to D4. This structural feature may suggest the order of 18 homotypic contact formation following ligand binding, i.e. formation of interactions in 19 D4 will be transmitted downstream to D5. It may also explain the possibility of 20 heterodimer formation (VEGFR-1/VEGFR-2 and VEGFR-2/VEGFR-3) by having one 21 interacting face rigid and fully conserved, and the other more flexible allowing for 22 differential bond formation. 23
Finally, the D7 interactions initially observed in VEGFR-2 (Yang et al., 2010) and 24 now confirmed for VEGFR-1 represent one more check-point in the formation of an 25 active receptor dimer. This additional restriction of mobility towards the transmembrane 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 domain is probably necessary for more stringent control of VEGFR activation 1 compared to the type III RTK family members. 2 Taken together, the availability of the structural details of the full-length VEGFR-3 1 ECD in complex with VEGF-A presented here allow a detailed mechanistic 4 interpretation of the role of individual Ig-domains in receptor dimerization and 5 activation. Most drugs targeting VEGF receptors to interfere with aberrant 6 vascularization available today are specific for VEGFR-2. The role of VEGFR-1 in 7 angiogenesis, and particularly in tumor angiogenesis, has recently attracted high 8 attention as it seems to be particularly relevant for de novo vascularization as 9 demonstrated for instance by Massena et al. (Massena et al., 2015) . Additional 10 relevance of VEGFR-1 in pathological angiogenesis has been observed in cancer 11 models (Van de Veire et al., 2010; Schomber et al., 2007) . The discovery of the 12 mechanism of receptor activity modulation by domains 4-7 described here opens new 13 possibilities for developing novel, highly specific VEGF receptor antagonists for future 14 medical applications. 15
16
EXPERIMENTAL PROCEDURES 17
Production and purification of recombinant proteins 18
Human VEGF-A121 (here denoted as VEGF-A) was produced in Pichia pastoris as 19 described before (Scheidegger et al., 1999) . Human VEGFR-1 D1-3 (residues 1-339), 20 D1-6 (residues 1-660), D2-7 (residues 132-750) and D1-7 (residues 1-750) were 21 expressed as secreted proteins in Sf21 insect cells, as described previously (Brozzo 22 et al., 2012) . The proteins were purified from culture supernatant by immobilized metal 23 affinity chromatography (IMAC) followed by size exclusion chromatography (SEC) on 24 Superdex 200 HR 16/600 (GE Healthcare) equilibrated in 25 mM HEPES pH 7.5 and 25 500 mM NaCl. For the formation of VEGFR-1 ECD/VEGF-A complexes, an equimolar 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 amount of receptor and ligand were mixed and the complexes were purified by SEC. The composite model of the VEGFR-1 D1-7/VEGF-A complex was converted into 22 density volume filtered to 25 Å resolution using the Bsoft software package (Heymann 23 and Belnap, 2007) . The volume was then used to calculate projections at an angular 24 interval of 15° with the SPIDER image processing suite (Frank et al., 1996) . The 25 projections with the most similar features to the experimental 2D averages were 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 selected. Density volumes and ribbon diagrams were displayed and oriented with the 1 UCSF Chimera package (Pettersen et al., 2004) . Crystallization. The VEGFR-1 D1-6/VEGF-A and the VEGFR-1 D2-7/VEGF-A 10 complexes used for crystallization were partially deglycosylated with PNG-ase F and 11 purified by SEC. Both complexes were crystallized in sitting drops at 20°C. The best 12 diffracting crystals of the VEGFR-1 D1-6/VEGF-A complex were obtained from a 13 reservoir solution containing 200 mM CaCl2, 100 mM MES pH 6.5 and 10-14% PEG 14 3000 (w/v) and of the VEGFR-1 D2-7/VEGF-A complex from a reservoir solution 15 containing 200 mM NaCl, 100 mM Na/K-phosphate pH 6.2 and 10% PEG 8000 (w/v). 16
The crystals of both complexes belonged to space group C2 with one complex per 17 asymmetric unit, a solvent content of 70% and the following cell parameters: VEGFR-18 1 D1-6/VEGF-A a=166.7, b=123.1, c=167.4 Å, β=109.6°; VEGFR-1 D2-7/VEGF-A 19 a=163.5, b=121.5, c=141.6 Å, β=90.02°. Iodide derivatives of the VEGFR-1 D1-20 6/VEGF-A complex were prepared by soaking the crystals in a reservoir solution 21 containing 100 mM CaCI2 for 3 hrs. For cryoprotection, the crystals were transferred 22 stepwise into mother liquor containing increasing concentrations of glycerol to a final 23 concentration of 20%, flash-frozen and stored in liquid nitrogen. 24
Structure determination. All datasets were collected on the X06DA beamline at the 25 Swiss Light Source (SLS) at the Paul Scherrer Institute in Villigen, Switzerland on a 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 PILATUS 2M detector (Dectris). A complete dataset to 4 Å resolution was collected 1 from a single native crystal of the VEGFR-1 D1-6/VEGF-A complex. Highly redundant 2 anomalous data were obtained from a single large crystal derivatized with iodide that 3 was measured on multiple positions and orientations using the high-precision multi-4 axis goniometer PRIGo . 5 Data were indexed, integrated and scaled with XDS (Kabsch, 1993) and further 6 processed with CCP4 programs (Collaborative Computational Project, 1994) . The 7 structure of the VEGFR-1 D1-6/VEGF-A complex was determined by a combination of 8 molecular replacement and single-wavelength anomalous dispersion (MR-SAD), as 9 implemented in the program suite PHASER (McCoy et al., 2007) . The partial molecular 10 replacement solution obtained using the structure of the VEGFR-1 D2/VEGF-A 11 complex (PDB ID: 1QTY) as a search model allowed for the identification of heavy 12 atom sites and substructure completion. Initial phases were improved by solvent 13 flattening and extended to 4 Å by two-fold NCS averaging with the program DM 14 (Cowtan et al., 2012) . The missing Ig-homology domains were positioned by phased 15 molecular replacement in MOLREP (Vagin and Teplyakov, 2010) using the following 16 structures as search models in the following order: for D4 VEGFR-3 D4 (PDB ID: 17 4BSJ), for D5 VEGFR-3 D5 (PDB ID: 4BSJ) and for D3 VEGFR-2 D3 (PDB ID: 2X1X). 18
To construct a model with the full VEGFR-1 sequence we created homology models 19 for the Ig-domains D3-D5 using the corresponding MR search models as templates in 20 SWISS-MODEL (Biasini et al., 2014) . The homology models were superimposed onto 21 the domains positioned by molecular replacement and single Ig-domains were 22 connected generating the VEGFR-1 D2-D5/VEGF-A model. 23
We first attempted to fit D1 and D6 using homology models as well, but the 24 resulting models had a poor fit without clear difference density to guide model building. 25
To overcome this, D1 and D6 were submitted to the Foldit structure prediction game 26 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 (Cooper et al., 2010) . Players were provided a set of five starting models from I-1 TASSER (Zhang, 2008) . Players then modified the structure to minimize the Rosetta 2 energy function. 339 and 443 players participated in the D1 and D6 puzzles, 3 respectively, over a two week period. A very diverse set of models was generated, 4 which were clustered to within 2 Å RMSD. The 1000 top-scoring models were then 5 used for molecular replacement with PHASER. A candidate model was chosen with 6 high log-likelihood gain and translational function Z-score for further manual refinement 7 ( Figure S2) . The D6 and D1 models were added sequentially to the VEGFR-1 D2-8 D5/VEGF-A model, followed by manual rebuilding in COOT (Emsley and Cowtan, 9 2004 ) and refinement in PHENIX (Adams et al., 2002) as for the homology models. 10 NCS, secondary-structure and reference structure restraints were applied throughout 11 the refinement process. For the final refined structure, Ramachandran values were: 12 82.2% favored, 14.4% allowed and 3.4% outlier. 13
The structure of the VEGFR-1 D2-7/VEGF-A complex was determined to 4.8 Å 14 resolution by molecular replacement in PHASER using the D2-6 part of the VEGFR-1 15 D1-6/VEGF-A structure and the structure of VEGFR-2 D7 dimer (PDB ID: 3KVQ) as 16 search models. The structure was improved by rigid-body refinement in PHENIX. A 17 composite model of the full-length VEGFR-1 extracellular domain/VEGF-A complex 18 was constructed in COOT by secondary-structure match (SSM) superposition of the 19 D1-6 and D2-7 structures (RMSD of 1.76 Å for 1128 residues of the D2-6 region). 20
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Supplemental Experimental Procedures
Size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS)
100 µl protein samples at a concentration of 1 mg/ml were injected onto a Superdex 200 HR 10/300 column for SEC-MALS determination (GE Healthcare). The column was equilibrated in 25 mM HEPES pH 7.5, 500 mM NaCl at 20°C, using an Agilent 1100 HPLC system. Light scattering and differential refractive index were recorded using a Wyatt miniDAWN Tristar detector and a Wyatt Optilab rRex detector, respectively. Wyatt Astra software was used to collect and process the data and to calculate the molar mass from a global fit of the light scattering signals from three detectors at different angles and the differential refractive index signal.
Small angle X-ray solution scattering (SAXS)
SAXS data acquisition was performed at the X12SA-beamline (cSAXS) at the Swiss Light Source at the Paul Scherrer Institute in Villigen, Switzerland, details are given in Supplemental Experimental Procedures. The intensities of the scattered X-rays were recorded on a Pilatus 2M detector using a wavelength of λ = 1 Å. Data was collected in the scattering vector range of 0.008 Å -1 -0.4 Å -1 , where the length of the scattering vector is given as s = 4πsinθ/λ (2θ is the scattering angle). Silver behenate was used as a standard for calibration of the s-range10.
Three concentrations were measured per protein sample using quartz capillaries with a diameter of 1 mm (Hilgenberg GmbH). To record background scattering, the protein buffer was measured in the same capillaries prior to protein data acquisition. Exposures of 0.5 s were taken at ten different spots along the capillary. The data was monitored for radiation damage and all frames showing no radiation damage were merged and averaged for further data processing. The collected SAXS data were integrated and radially averaged utilizing our own MATLAB-scripts (J. Missimer & K. Kisko, unpublished) . Using PRIMUS from the ATSAS (Petoukhov et al., 2012) program package14, the background scattering was subtracted and data of different concentrations were merged. In order to check for proper protein folding of all measured samples Kratky-plots were calculated. The distance distribution function P(r) was calculated using GNOM and the program AUTOGNOM.
Negative stain single particle electron microscopy (EM)
In order to stabilize the VEGFR-1 D1-7/VEGF-A complex for negative stain EM, samples were prepared using GraFix (ref. (Kastner et al., 2008) quenching buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 0.4 M glycine). For negative stain EM, 5 μl of undiluted sample was adsorbed to a freshly glow discharged thin carbon film supported on a 200 mesh copper grid and incubated for 1 min. at room temperature. The excess sample was blotted away using filter paper. Three consecutive washes using 20 mM HEPES pH 7.5, 150 mM NaCl and one wash with 2% uranyl acetate was performed followed by 20 s staining with fresh 2% uranyl acetate. Negative stain EM data were collected on a CM-100 microscope (Philips) equipped with a Veleta 2k x 2k CCD camera (Olympus). The voltage used was 80 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 kV and the magnification was set to a nominal value of 130'000 x. From 126 micrographs 4883 particles were picked manually using XMIPP (Scheres et al., 2008) . Inferior particles and particles with a z-score >3 were discarded. 4536 particles were boxed in 100 x 100 pixel boxes and subjected to alignment and classification into 24 2D class averages using maximum-likelihood target function (ML2D) implemented in XMIPP using 100
iterations (Scheres et al., 2005) . After 49 iterations ML2D reached convergence.
Isothermal titration calorimetry (ITC)
The measurements on VEGFR-1 were performed at 20°C in 25 mM HEPES pH 7.5, and 150 mM NaCl (ITCbuffer) using an iTC200 calorimeter (MicroCal ® , GE Healthcare). The proteins were purified on a Superdex 200 10/300 column (GE Healthcare) equilibrated in ITC-buffer and dialyzed against ITC-buffer overnight at 4°C prior to analysis. The calorimeter cell contained VEGFR-1 D1-7 or VEGFR-1 D1-3 at concentrations ranging from 4.4
to 30 μM and the ligand VEGF-A121 was used in the syringe at concentrations ranging from 22.5 to 100 μM. All samples were equilibrated to the measurement temperature and degassed prior to ITC analysis. The following settings were applied: one initial injection of 1 μl followed by 15 injections of 2.6 μl at an injection speed of 1 μl/s with a data filter of 1 s and 300 s recovery time between each peak. The software Origin 7.0 (OriginLab ® ) was used for data analysis.
Cell transfection and determination of receptor activity
NIH 3T3 cells were transfected using a modified peGFP-N1 vectors (Takara Bio Europe/Clontech) carrying either wt VEGFR-2, or a mutant T446E/K512A where residue K512 was replaced by A and T446 by E. In addition, a chimeric VEGFR (VEGFR-1/2) consisting of the wt or a mutant VEGFR-1 ECD (residues 1-752) and the intracellular domain of VEGFR-2 (residues 759-1356) was generated. The mutant used was E513K/K517A. All expression vectors were generated by Gibson assembly (Gibson et al., 2009 ). 8 µg DNA in 0.8 ml serum-free medium were mixed with 16 µl PEI (Polyethyleneimine, stock 1 mg/ml, Aldrich 408727, 25 kDa branched), incubated for 10 minutes at RT for the complex to form. The medium in the culture dishes was replaced with 1.6 ml DMEM containing 0.5% serum and the DNA/PEI complex was added for 5 hrs. Cells were incubated for 20 hrs after addition of 1 ml DME with 10% serum. The cells were serum-starved in DMEM supplemented with 1% bovine serum albumin (BSA) and stimulated with 1.5 nM VEGF-A for 10 min at 37°C. Cell lysates were prepared in lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, and 0.5% w/v Triton X-100) supplemented with protease inhibitor cocktail (Roche diagnostics, Risch-Rotkreuz Switzerland), phosphatase inhibitors (200 μM Na3VO4, 10 mM NaF, 10 mM sodium pyrophosphate, 30 mM p-nitrophenyl-phosphate, 80 mM glycerophosphate, and 20 μM phenylarsine oxide), and 10% glycerol. Cell lysates were diluted with Lämmli buffer (20 mM Tris pH 6.8, 5%
SDS, 10% mercaptoethanol, 0.02% bromphenol blue) and the proteins separated on 8% SDS polyacrylamide gels and blotted to Polyvinylidene (PVDF, Thermofisher Scientific, Zug Switzerland) membranes. We used 55B11
(2479, Cell Signaling Technology Europe) and phospho-Y1175 (2478, Cell Signaling Technology Europe) for VEGFR-2 and VEGFR-1/2 detection. All primary antibodies were used at dilutions of 1:1'000, followed by secondary alkaline phosphatase-coupled antibodies (6440-04, Southern Biotech, Birmingham USA) at a dilution of 1:10'000. The blots were developed with AP chemiluminescent detection substrate (Life Technologies, Carlsbad USA) and the immunoblots were analyzed on a GE Healthcare ImageQuant RT ECL scanner and densitometrically quantified with ImageQuant TL software (GE Healthcare Europe GmbH, Glattbrugg, Switzerland) .   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
